Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of Oral FB-101 in Healthy Adult Males
NCT07126704Phase 1Not yet recruiting
- Sponsor
- 1ST Biotherapeutics
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FB-101 (9 arms), sponsored by 1ST Biotherapeutics. Primary endpoint: Treatment-Emergent Adverse Events up to 2 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
FB-101
Beyond the preview
Go deeper on NCT07126704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126704.